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ABSTRACT
This study assessed the influence of steroidal contraceptives on liver enzymes and serum total protein using 48 adult 
female rats in four groups -A as control and B, C and D as tests. The animals were further divided into two 
subgroups - treatment (A1 - D1; n=6 each) and reversal (A2 - D2; n=6 each). Groups A1&A2 received normal feed 
and water only, while B1&B2, C1&C2 and D1&D2, respectively received 0.03mg/kg of Norethisterone enantate
intramuscularly once in 6 days for 3 estrous cycles; 0.03mg/kg of Lynesternol daily for 6 days and repeatedly for 3 
estrous cycles; and a combination of 0.03mg/kg of Ethinylestradiol and 0.03mg of Levonorgestrel daily for 6 days 
and repeatedly for 3 estrous cycles. At the end of the treatment phase, blood samples were collected from groups A1
- D1 for laboratory analysis, while the treatments for groups B2 - D2, were suspended and monitored for same 
period (reversal phase) prior to blood sample collection and analysis. The results affirmed that steroidal 
contraceptives had capacity to induce significant elevation and reduction in levels of liver enzymes and serum total 
protein respectively; hence the call for caution to avoid unwarranted complications.
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INTRODUCTIION 
Insinuations that many women stop using contraceptives due to issues associated with weight gain, water retention, 
hypertension and venous and arterial cardiovascular complications (Gate and Stone, 1992, Burkman et al., 2001; 
Kemmeran et al., 2002; Baillargeon et al., 2005a, b) has become a source of worry. Other minor but common side 
effects of steroidal contraceptives severe enough to cause the discontinuation of its usage, have also been identified 
to include nausea, breast tenderness, irregular menstrual bleeding and thrombosis (ACOG Practice Bulletin, 2006).
Nevertheless, the last 30 years has witnessed the development of formulations with decreasing doses of estrogen and 
progestin and their use have been associated with very low pregnancy rates akin to those with higher doses of 
steroids (Vessey et al., 2010). Although the use of contraceptives has tremendously reduced unsafe abortion and 
maternal/neonatal death rates by 25% (Olise, 2011), there is still the need to examine the long term effects of its 
usage on vital organs of the body such as the liver-being the principal organ for maintaining the internal 
environment of the body (Aashish et al.,2012). 
Hargreaves (1969) had several years ago, stated that the liver plays a central role in the metabolism of contraceptives 
and it has become obvious that these substances can act directly or indirectly on the liver to produce a variety of 
biological effects; some of which have both physiological and pathological significance. He added also that oral 
contraceptives can induce liver damage, jaundice and hepatic abnormalities (Hargreaves, 1969). Similarly, there are 
documented facts that the long term usage of oral contraceptive (OCS) has been associated with altered immunity
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leading to increased vulnerability to respiratory, digestive, urogenital and musculoskeletal system diseases (Swain, 
1991) as well as blood coagulation disorders (Chadwick, et al., 2002), jaundice, deep vein thrombosis, 
thromboembolic disease and gallbladder disease (Fernandez and Kaplowitz, 2005).  This study therefore, assesses
the influence of steroidal contraceptives on liver enzymes and serum total proteins in female white albino Wistar 
rats.
MATERIALS AND METHODS
Experimental Animals/Grouping: Forty-eight (48) adult female Wistar rats were used for this study. They were 
obtained from the laboratory animal farm of Anthonio Research Center, Ekpoma, Edo State, Nigeria, and 
transported to the experimental site where the animals were housed in a well-ventilated room under 12/12 hours 
light/dark cycle and fed with growers mash produced by Grand Cereals Ltd -a subsidiary of UAO Nigeria PLC, Jos, 
Plateau State. Water was given ad libitum. The animals were divided into four groups (A, B, C and D). Group A 
served as control, while B, C and D served as the test groups. The animals in each of the groups were further divided 
into two subgroups - treatment (A1 - D1; n=6 each) and reversal (A2 - D2; n=6 each) groups. 
Drugs of study/Administration: The drugs of study were Norethisterone enantate, Lynesternol, Ethinylestradiol
and Levonorgestrel. Groups A1&A2 received feed and water only, while B1&B2, C1&C2 and D1&D2, respectively 
received 0.03mg/kg of Norethisterone enantate intramuscularly once in 6 days for 3 estrous cycles; 0.03mg/kg of 
Lynesternol daily for 6 days and repeatedly for 3 estrous cycles; and a combination of 0.03mg/kg of Ethinylestradiol
and 0.03mg of Levonorgestrel daily for 6 days and repeatedly for 3 estrous cycles. The drugs were administered 
according to the procedures described by Ekhator and Osifo (2012).  
Sample Collection: At the end of each of experimental phases –treatment and reversal, blood samples were 
collected from each of the rats via a cardiac puncture using 5ml syringe and needle under diethyl ether anesthesia. 
Sample Analysis: The levels Aspartate Transaminase (AST), Alkaline Phosphataes (ALP) and Alanine 
Transaminase (ALT) were determined according to procedures described by Olomo (2012), while Serum Total 
Protein was determined according to procedures described by Yolton et al. (1994).
Data Analysis: Data analysis was performed using the Scientific Package of Social Sciences (SPSS version 19)
software. The significance level was set at p<0.05. 
RESULTS
As compared to the control values, the different steroidal contraceptives were observed to have induced significant 
elevations (p<0.05) in ALP, AST and ALT levels for groups B(1), C(1) and D(1), but their withdrawal in the 
reversal phase induced reductions (p<0.05) in the ALP, AST and ALT values for groups B(2), C(2) and D(2), as 
compared to groups B(1), C(1) and D(1); being statistically significant in ALP values for all the groups, but the AST 
values for groups B(2) and D(2) (see table 1). 
Table 1: Effects of Different Steroidal Contraceptives on Liver Enzymes and Serum Total Protein
Liver enzymes Subgroups
Group
A B C D
ALP (u/l) 1 92.00±11.88 161.33±31.06* 212.97±11.90* 53.33±36.86*
2 92.70±12.47 142.08±28.68* 186.92±31.83* 42.32±36.75*
ALT (u/l) 1 46.92±17.27 50.09±8.81 66.36±33.33 58.71±40.48
2 46.43±4.86 40.85±18.93 47.66±9.31 40.97±19.82
AST (u/l) 1 120.93±1.39 163.85±43.02 160.35±35.02 148.15±5.94
2 114.49±4.93 133.67±8.83* 153.06±18.58 121.42±22.59*
Serum total 
protein (g/dl)
1 9.47±0.71 6.55±0.63 5.62±0.85 5.65±0.10
2 9.91± 0.10 9.17±1.31 10.16±0.93 6.39±1.06
Key: 1 = Treatment phase; 2 = Reversal (withdrawal) phase; *mean difference is significant at p<0.05. 
All the values are expressed as mean ± standard deviation.
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The results on Serum total protein showed that the administration of steroidal contraceptives led to reductions in
total protein levels in test groups B, C and D, compared to the control, but the observed differences were not 
statistically significant. Interestingly, the reversal phase results showed elevations in total protein levels in group B, 
C and D, when compared with their values at the end of the treatment phase. However, the values remained lower 
than the control groups in B and D, except group C with slightly higher total protein level than the control (see table 
2). The differences in the reversal phase were not statistically significant.   
DISCUSSION
The result of this study does affirm the capacity of steroidal contraceptives to induce elevations in serum liver 
enzymes irrespective of the type administered to the animals. The observed elevations were in line with the reports 
by Hargreaves et al. (2013), Swain (1991) and Rickenlund et al. (2004), but the changes in Serum Total Protein 
contradicted the finding by Lonnerdal et al. (1980) who had reported a significant elevation in the concentration of 
total protein in women on long term oral contraceptives. Nevertheless, a brief communication by Huisveld et al.
(1987) had indicated the potential influence of contraceptives on protein metabolism as reflected by an observed 
capacity to reduced total protein S but not free protein S. 
Attention can also be drawn to the report by Duvillard et al. (2010) that estrogen-containing oral contraceptives has 
the capacity to cause elevations in the levels of very low density lipoprotein, but reduction in the levels of plasma 
high density lipoprotein. These shades of opinion, irrespective of the divide, suggests that the findings highlight 
contraceptives’ capacity to alter vital metabolic processes either negatively or positively, and in a manner that 
seemingly remain unpredictable due to various factor variations –physiologic, environmental and/or possibly 
pathologic. In one instance, Adesiyan et al. (2011) opined that the use of hormonal contraceptives could negatively 
impact on infants thriving on exclusive breast feeding after having monitored the capacity of contraceptives to 
induce significant reductions in breast milk glucose in lactating mothers; exemplifying further, the dimensions of the 
side effects of contraceptive usage. 
Undoubtedly, the observed elevations in the transaminases portrayed a classical case of ‘drug induced 
hepatotoxicity’ which, according to Aashish et al. (2012), has been implicated in 5% of all hospital admissions and 
50% of all acute liver failures. Such elevations simply depict hepatocelluar death (Amacher, 1998; Edoardo, 2005)
and/or fatty degeneration in particular (Amacher, 1998); though it can also be used in conjunction with other serum 
enzymes, in distinguishing non-hepatocellular injury (Amacher, 1998). Similarly, the observed reduction in the 
serum total protein levels accentuate the capacity of contraceptives to induce liver disease and thus, suggests that 
long term administration of steroidal contraceptives may be deleterious to the liver. In fact, the reversal stage 
changes did signify that early withdrawals following monitored symptoms of contraceptive usage can help restore 
normalcy if an irreversible damage hasn’t occurred. Thus, to avoid unwarranted complications, the need for caution 
in the use of contraceptives cannot be overemphasized.
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